Kif14 overexpression accelerates murine retinoblastoma development

Michael O'Hare, Mehdi Shadmand, Rania S. Sulaiman, Kamakshi Sishtla, Toshiaki Sakisaka, Timothy Corson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The mitotic kinesin KIF14 has an essential role in the recruitment of proteins required for the final stages of cytokinesis. Genomic gain and/or overexpression of KIF14 has been documented in retinoblastoma and a number of other cancers, such as breast, lung and ovarian carcinomas, strongly suggesting its role as an oncogene. Despite evidence of oncogenic properties in vitro and in xenografts, Kif14's role in tumor progression has not previously been studied in a transgenic cancer model. Using a novel Kif14 overexpressing, simian virus 40 large T-antigen retinoblastoma (TAg-RB) double transgenic mouse model, we aimed to determine Kif14's role in promoting retinal tumor formation. Tumor initiation and development in double transgenics and control TAg-RB littermates were documented in vivo over a time course by optical coherence tomography, with subsequent ex vivo quantification of tumor burden. Kif14 overexpression led to an accelerated initiation of tumor formation in the TAg-RB model and a significantly decreased tumor doubling time (1.8 vs. 2.9 weeks). Moreover, overall percentage tumor burden was also increased by Kif14 overexpression. These data provide the first evidence that Kif14 can promote tumor formation in susceptible cells in vivo.

Original languageEnglish (US)
Pages (from-to)1752-1758
Number of pages7
JournalInternational Journal of Cancer
Volume139
Issue number8
DOIs
StatePublished - Oct 15 2016

Fingerprint

Retinoblastoma
Viral Tumor Antigens
Neoplasms
Tumor Burden
Retinal Neoplasms
Kinesin
Cytokinesis
Simian virus 40
Optical Coherence Tomography
Oncogenes
Heterografts
Transgenic Mice
Breast
Carcinoma
Lung

Keywords

  • kinesin
  • oncogene
  • optical coherence tomography
  • retinoblastoma
  • transgenic mouse

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

O'Hare, M., Shadmand, M., Sulaiman, R. S., Sishtla, K., Sakisaka, T., & Corson, T. (2016). Kif14 overexpression accelerates murine retinoblastoma development. International Journal of Cancer, 139(8), 1752-1758. https://doi.org/10.1002/ijc.30221

Kif14 overexpression accelerates murine retinoblastoma development. / O'Hare, Michael; Shadmand, Mehdi; Sulaiman, Rania S.; Sishtla, Kamakshi; Sakisaka, Toshiaki; Corson, Timothy.

In: International Journal of Cancer, Vol. 139, No. 8, 15.10.2016, p. 1752-1758.

Research output: Contribution to journalArticle

O'Hare, M, Shadmand, M, Sulaiman, RS, Sishtla, K, Sakisaka, T & Corson, T 2016, 'Kif14 overexpression accelerates murine retinoblastoma development', International Journal of Cancer, vol. 139, no. 8, pp. 1752-1758. https://doi.org/10.1002/ijc.30221
O'Hare, Michael ; Shadmand, Mehdi ; Sulaiman, Rania S. ; Sishtla, Kamakshi ; Sakisaka, Toshiaki ; Corson, Timothy. / Kif14 overexpression accelerates murine retinoblastoma development. In: International Journal of Cancer. 2016 ; Vol. 139, No. 8. pp. 1752-1758.
@article{4579c1d14ad3475a84f7615c6f1c71ee,
title = "Kif14 overexpression accelerates murine retinoblastoma development",
abstract = "The mitotic kinesin KIF14 has an essential role in the recruitment of proteins required for the final stages of cytokinesis. Genomic gain and/or overexpression of KIF14 has been documented in retinoblastoma and a number of other cancers, such as breast, lung and ovarian carcinomas, strongly suggesting its role as an oncogene. Despite evidence of oncogenic properties in vitro and in xenografts, Kif14's role in tumor progression has not previously been studied in a transgenic cancer model. Using a novel Kif14 overexpressing, simian virus 40 large T-antigen retinoblastoma (TAg-RB) double transgenic mouse model, we aimed to determine Kif14's role in promoting retinal tumor formation. Tumor initiation and development in double transgenics and control TAg-RB littermates were documented in vivo over a time course by optical coherence tomography, with subsequent ex vivo quantification of tumor burden. Kif14 overexpression led to an accelerated initiation of tumor formation in the TAg-RB model and a significantly decreased tumor doubling time (1.8 vs. 2.9 weeks). Moreover, overall percentage tumor burden was also increased by Kif14 overexpression. These data provide the first evidence that Kif14 can promote tumor formation in susceptible cells in vivo.",
keywords = "kinesin, oncogene, optical coherence tomography, retinoblastoma, transgenic mouse",
author = "Michael O'Hare and Mehdi Shadmand and Sulaiman, {Rania S.} and Kamakshi Sishtla and Toshiaki Sakisaka and Timothy Corson",
year = "2016",
month = "10",
day = "15",
doi = "10.1002/ijc.30221",
language = "English (US)",
volume = "139",
pages = "1752--1758",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Kif14 overexpression accelerates murine retinoblastoma development

AU - O'Hare, Michael

AU - Shadmand, Mehdi

AU - Sulaiman, Rania S.

AU - Sishtla, Kamakshi

AU - Sakisaka, Toshiaki

AU - Corson, Timothy

PY - 2016/10/15

Y1 - 2016/10/15

N2 - The mitotic kinesin KIF14 has an essential role in the recruitment of proteins required for the final stages of cytokinesis. Genomic gain and/or overexpression of KIF14 has been documented in retinoblastoma and a number of other cancers, such as breast, lung and ovarian carcinomas, strongly suggesting its role as an oncogene. Despite evidence of oncogenic properties in vitro and in xenografts, Kif14's role in tumor progression has not previously been studied in a transgenic cancer model. Using a novel Kif14 overexpressing, simian virus 40 large T-antigen retinoblastoma (TAg-RB) double transgenic mouse model, we aimed to determine Kif14's role in promoting retinal tumor formation. Tumor initiation and development in double transgenics and control TAg-RB littermates were documented in vivo over a time course by optical coherence tomography, with subsequent ex vivo quantification of tumor burden. Kif14 overexpression led to an accelerated initiation of tumor formation in the TAg-RB model and a significantly decreased tumor doubling time (1.8 vs. 2.9 weeks). Moreover, overall percentage tumor burden was also increased by Kif14 overexpression. These data provide the first evidence that Kif14 can promote tumor formation in susceptible cells in vivo.

AB - The mitotic kinesin KIF14 has an essential role in the recruitment of proteins required for the final stages of cytokinesis. Genomic gain and/or overexpression of KIF14 has been documented in retinoblastoma and a number of other cancers, such as breast, lung and ovarian carcinomas, strongly suggesting its role as an oncogene. Despite evidence of oncogenic properties in vitro and in xenografts, Kif14's role in tumor progression has not previously been studied in a transgenic cancer model. Using a novel Kif14 overexpressing, simian virus 40 large T-antigen retinoblastoma (TAg-RB) double transgenic mouse model, we aimed to determine Kif14's role in promoting retinal tumor formation. Tumor initiation and development in double transgenics and control TAg-RB littermates were documented in vivo over a time course by optical coherence tomography, with subsequent ex vivo quantification of tumor burden. Kif14 overexpression led to an accelerated initiation of tumor formation in the TAg-RB model and a significantly decreased tumor doubling time (1.8 vs. 2.9 weeks). Moreover, overall percentage tumor burden was also increased by Kif14 overexpression. These data provide the first evidence that Kif14 can promote tumor formation in susceptible cells in vivo.

KW - kinesin

KW - oncogene

KW - optical coherence tomography

KW - retinoblastoma

KW - transgenic mouse

UR - http://www.scopus.com/inward/record.url?scp=84981277355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981277355&partnerID=8YFLogxK

U2 - 10.1002/ijc.30221

DO - 10.1002/ijc.30221

M3 - Article

C2 - 27270502

AN - SCOPUS:84981277355

VL - 139

SP - 1752

EP - 1758

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -